Ausgabe 3/2017
Inhalt (21 Artikel)
Artemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectives
Archana Bhaw-Luximon, Dhanjay Jhurry
Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting
Joseph V. Pergolizzi Jr., Robert Taylor, Jo Ann LeQuang, Gianpietro Zampogna, Robert B. Raffa
Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer
Jing Zhang, Jinyu Liu, Xinyan Xu, Li Li
Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer
Toshio Shimizu, Kimio Yonesaka, Hidetoshi Hayashi, Tsutomu Iwasa, Koji Haratani, Hironori Yamada, Shoichi Ohwada, Emi Kamiyama, Kazuhiko Nakagawa
Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer
Hisao Imai, Tomohito Kuwako, Kyoichi Kaira, Tomomi Masuda, Yosuke Miura, Kaori Seki, Reiko Sakurai, Mitsuyoshi Utsugi, Kimihiro Shimizu, Noriaki Sunaga, Yoshio Tomizawa, Shinichi Ishihara, Takao Ishizuka, Akira Mogi, Takeshi Hisada, Koichi Minato, Atsushi Takise, Ryusei Saito, Masanobu Yamada
Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans
Yihua E. Ye, Caroline N. Woodward, Narayana I. Narasimhan
Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial
Junichi Koike, Kimihiko Funahashi, Kazuhiko Yoshimatsu, Hajime Yokomizo, Hayato Kan, Takeshi Yamada, Hideyuki Ishida, Keiichiro Ishibashi, Yoshihisa Saida, Toshiyuki Enomoto, Kenji Katsumata, Masayuki Hisada, Hirotoshi Hasegawa, Keiji Koda, Takumi Ochiai, Kazuhiro Sakamoto, Hiroyuki Shiokawa, Shimpei Ogawa, Michio Itabashi, Shingo Kameoka
Effect of food on the bioavailability of palbociclib
Ana Ruiz-Garcia, Anna Plotka, Melissa O’Gorman, Diane D. Wang
Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients
Zhan Wang, Juan Chen, Mei-Zuo Zhong, Juan Huang, Yuan-Ping Hu, De-Yun Feng, Zhi-Jiao Zhou, Xiao Luo, Zhao-Qian Liu, Wu-Zhong Jiang, Wei-Bing Zhou
An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitor
Melanie I. Titze, Otmar Schaaf, Marco H. Hofmann, Michael P. Sanderson, Stephan K. Zahn, Jens Quant, Thorsten Lehr
Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies
Peter N. Morcos, Katrijn Bogman, Stanislas Hubeaux, Carolina Sturm-Pellanda, Thorsten Ruf, Walter Bordogna, Sophie Golding, Ali Zeaiter, Markus Abt, Bogdana Balas
NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis
Toshihiko Doi, Tetsuya Hamaguchi, Kohei Shitara, Satoru Iwasa, Yasuhiro Shimada, Mitsunori Harada, Kenichiro Naito, Naoto Hayashi, Atsuhiro Masada, Atsushi Ohtsu
Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab
Hidekazu Kuramochi, Masayuki Ando, Michio Itabashi, Go Nakajima, Kazuyuki Kawakami, Mie Hamano, Eiichi Hirai, Hajime Yokomizo, Ryuji Okuyama, Tatsuo Araida, Kazuhiko Yoshimatsu, Shingo Kameoka, Kazuhiko Hayashi
Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer
Rajendar K. Mittapalli, Silpa Nuthalapati, Stacie Peacock Shepherd, Hao Xiong
Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy
Akiyoshi Kasuga, Yasuo Hamamoto, Ayano Takeuchi, Kenta Kawasaki, Takeshi Suzuki, Kenro Hirata, Yasutaka Sukawa, Hiromasa Takaishi, Takanori Kanai
A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma
Jennifer L. Clarke, Annette M. Molinaro, Juan R. Cabrera, Ashley A. DeSilva, Jane E. Rabbitt, Joshua Prey, Daryl C. Drummond, Jaeyeon Kim, Charles Noble, Jonathan B. Fitzgerald, Susan M. Chang, Nicholas A. Butowski, Jennie W. Taylor, John W. Park, Michael D. Prados
Phase I study of pazopanib plus TH-302 in advanced solid tumors
Richard F. Riedel, Kellen L. Meadows, Paula H. Lee, Michael A. Morse, Hope E. Uronis, Gerard C. Blobe, Daniel J. George, Jeffrey Crawford, Donna Niedzwiecki, Christel N. Rushing, Christy C. Arrowood, Herbert I. Hurwitz
Impact of Laparotomy and Intraperitoneal Hyperthermic Instillation (LIHI) on the oxaliplatin pharmacokinetics after intravenous administration in Wistar rats
María Isabel Mas-Fuster, Amelia Ramon-Lopez, Javier Lacueva, Antonio Compañ, Patricio Más-Serrano, Ricardo Nalda-Molina
Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia
Yoshitaka Nishikawa, Taro Funakoshi, Takahiro Horimatsu, Shin’ichi Miyamoto, Takeshi Matsubara, Motoko Yanagita, Shunsaku Nakagawa, Atsushi Yonezawa, Kazuo Matsubara, Manabu Muto